Baculoviral IAP repeat-containing protein 5 promoter (BIRC5 promoter)

The Baculoviral IAP repeat-containing protein 5 (BIRC5) promoter, commonly known as the survivin promoter, is a critical DNA regulatory sequence that governs the transcription of the survivin gene. Survivin is a unique member of the inhibitor of apoptosis (IAP) family because it is highly expressed during fetal development and in nearly all human cancers, but is largely undetectable in normal, terminally differentiated adult tissues [2, 4]. This tumor-specific activity makes the survivin promoter an attractive tool for cancer-selective gene therapy, where it can be used as a molecular switch to drive the expression of therapeutic genes, such as toxins or cytokines, specifically within malignant cells [7, 11]. Additionally, small molecules like sepantronium bromide (YM155) and terameprocol (EM-1421) have been developed to suppress survivin expression by targeting its promoter activity, often by disrupting the binding of transcription factors like Sp1 or ILF3 [1, 2, 10]. Inhibiting the survivin promoter leads to increased apoptosis and sensitized tumor cells to chemotherapy and radiation [12, 15]. Despite its high tumor specificity, therapeutic strategies must account for potential low-level activity in normal proliferating cells such as hematopoietic stem cells and the intestinal epithelium [2, 10].

Other names

Survivin promoterBIRC5 gene promoterTIAP promoterAPI4 promoter

Transcriptional inhibition of the BIRC5 gene by disrupting transcription factor binding (e.g., Sp1, ILF3) or utilizing the promoter's tumor-specific activity to drive the expression of therapeutic transgenes in gene therapy applications [1, 2, 7].